Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro

被引：0
|
作者：
Daisuke Kawasaki
Yutaka Emori
Runa Eta
Yuka Iino
Hiroki Hamano
Koji Yoshinaga
Takao Tanaka
Mineo Takei
Susan A. Watson
机构：
[1] Zeria Pharmaceutical Co.,Central Research Laboratories
[2] Ltd,Division of Pre
[3] University of Nottingham,Clinical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 61卷
关键词：
Z-360; Gastrin; Cholecystokinin (CCK)-2/gastrin receptor; Antagonist; Pancreatic carcinoma; Gemcitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：883 / 892
页数：9
相关论文
共 2 条
  • [1] Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro
    Kawasaki, Daisuke
    Emori, Yutaka
    Eta, Runa
    Iino, Yuka
    Hamano, Hiroki
    Yoshinaga, Koji
    Tanaka, Takao
    Takei, Mineo
    Watson, Susan A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 883 - 892
  • [2] Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
    Kobayashi, Nobuyoshi
    Seto, Koichi
    Orikawa, Yuki
    Hamano, Hiroki
    Yoshinaga, Koji
    Takei, Mineo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (02) : 216 - 222
1